News for Healthier Living

ASH: Triplet combination regimens demonstrate high response rates in multiple leukemias

Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant positive results from novel triplet therapies in the treatment of relapsed or refractory and newly diagnosed leukemias. The results were presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. More information on all ASH Annual Meeting content from MD Anderson can be found at MDAnderson.org/ASH.

December 9, 2024


December 21 2024

December 20 2024

December 19 2024

December 18 2024

December 17 2024

December 16 2024

December 15 2024

December 14 2024

December 13 2024

December 12 2024

December 11 2024

December 10 2024

December 9 2024

December 8 2024

December 7 2024